Myostatin, also known as growth differentiation factor 8 (GDF-8), is a protein that acts as a negative regulator of skeletal muscle mass. It was discovered by Se-Jin Lee and Alexandra McPherron at Johns Hopkins University in 1997. Mice lacking the myostatin gene develop dramatically increased muscle mass (McPherron et al., 1997), a finding that launched decades of research into therapeutic myostatin inhibition.
The convergence of widespread GLP-1 receptor agonist use (associated in trials with reductions in lean mass alongside fat mass) and an ageing global population facing sarcopenia has made myostatin inhibitors one of the most commercially promising peptide/biologic categories in development.
How Myostatin Inhibition Works
Myostatin signals through the activin type II receptor (ActRII), specifically ActRIIA and ActRIIB, on muscle cell surfaces. This signalling activates the SMAD2/3 pathway, which suppresses muscle protein synthesis and promotes muscle protein breakdown.
Blocking this pathway can be achieved at several points:
- Anti-myostatin antibodies: Bind myostatin directly, preventing receptor interaction
- ActRII receptor blockers: Block the receptor myostatin binds to (broader mechanism, also blocks activin A and GDF-11)
- Follistatin: A natural myostatin-binding protein that neutralises myostatin activity
- Propeptide inhibitors: Target the myostatin propeptide to prevent activation
Bimagrumab: The Leading Candidate
Bimagrumab is a human monoclonal antibody that blocks ActRII (both ActRIIA and ActRIIB). It was originally developed by Novartis (Heymsfield et al., 2021) and is now developed by Eli Lilly through its subsidiary Versanis Bio (Heymsfield et al., 2026). It is the most advanced myostatin pathway inhibitor with clinical data in metabolic disease.
Key Clinical Data
| Trial | Population | Results |
|---|---|---|
| Heymsfield et al. (2021), JAMA Network Open | 75 adults with type 2 diabetes and overweight or obesity | Bimagrumab alone: 6.5% total body-weight reduction, 3.6% lean mass gain, 20.5% fat mass reduction over 48 weeks |
| Heymsfield et al. (2026), Nature Medicine (BELIEVE, Phase 2) | 507 adults with obesity | High-dose bimagrumab plus semaglutide: 22.1% body-weight reduction by 72 weeks (15.7% with semaglutide alone), with about 92% of the reduction attributable to fat mass (versus about 71% to 76% with semaglutide alone) |
The bimagrumab plus semaglutide combination data is particularly significant to researchers. Weight loss, including with drug treatment, is typically about 60 to 75% fat mass and 25 to 40% lean tissue (Heymsfield et al., 2026). Adding bimagrumab shifted this ratio to about 92% fat mass in the trial cohort, a finding of interest for research into lean mass preservation alongside GLP-1 mechanisms.
Apitegromab
Developed by Scholar Rock, apitegromab selectively binds the precursor (pro and latent) forms of myostatin, blocking its activation. Unlike bimagrumab, it did not bind activin A or GDF-11 in laboratory studies, where it was called SRK-015 (Pirruccello-Straub et al., 2018), which may reduce off-target effects. In September 2026 the FDA approved it for spinal muscular atrophy (SMA) in people aged two and over who already receive an SMN2-targeted treatment, based on the Phase 3 SAPPHIRE trial (Scholar Rock announcement). In metabolic research, the company reports that its completed Phase 2 EMBRAZE study showed lean mass preservation during tirzepatide-induced weight loss (Scholar Rock, January 2026).
Relevance to Ongoing Peptide Research
The intersection of GLP-1 mechanism research and myostatin inhibition represents one of the largest commercial opportunities in metabolic medicine. Tens of millions of people worldwide are now prescribed semaglutide and tirzepatide. Trial data indicates a significant proportion experience reductions in lean mass. A companion research compound that preserves lean tissue while maintaining fat mass reduction could become a standard part of GLP-1 treatment research going forward.
For further reading on lean mass and GLP-1 mechanism research, see the research overview.
Non-Pharmaceutical Approaches Under Study
While no pharmaceutical myostatin inhibitor is approved outside SMA, several approaches have been studied for an association with lower myostatin expression:
- Resistance training: The most studied non-pharmaceutical factor associated with reduced myostatin expression. Nine weeks of heavy-resistance knee extension training reduced muscle myostatin mRNA by 37% in a study of 15 adults (Roth et al., 2003).
- Creatine: In an 8-week trial in 27 young men, creatine taken alongside resistance training lowered serum myostatin more than training alone (Saremi et al., 2010).
- Epicatechin: A flavanol found in dark chocolate that lowered myostatin in mice and raised the plasma follistatin to myostatin ratio in a small 7-day human study (Gutierrez-Salmean et al., 2014).
- Vitamin D: In mouse muscle cells (C2C12) grown in the laboratory, the active form of vitamin D reduced myostatin expression; this is a cell-culture finding (Garcia et al., 2011).
Timeline and Market Outlook
Bimagrumab has not yet reached Phase 3 in obesity: as of October 2026, ClinicalTrials.gov lists Phase 2 studies with semaglutide and with tirzepatide (for example NCT06643728), so any approval timeline for a bimagrumab plus GLP-1 combination is uncertain. Apitegromab, by contrast, was approved by the FDA for SMA in September 2026. This category could become the next major chapter in the peptide research story.
References
- Garcia LA, et al. (2011). 1,25(OH)2vitamin D3 stimulates myogenic differentiation by inhibiting cell proliferation and modulating the expression of promyogenic growth factors and myostatin in C2C12 skeletal muscle cells. Endocrinology. PubMed 21673099
- Gutierrez-Salmean G, et al. (2014). Effects of (-)-epicatechin on molecular modulators of skeletal muscle growth and differentiation. Journal of Nutritional Biochemistry. PubMed 24314870
- Heymsfield SB, et al. (2021). Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial. JAMA Network Open. PubMed 33439265
- Heymsfield SB, et al. (2026). Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nature Medicine. PubMed 41772149
- McPherron AC, et al. (1997). Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. PubMed 9139826
- Pirruccello-Straub M, et al. (2018). Blocking extracellular activation of myostatin as a strategy for treating muscle wasting. Scientific Reports. PubMed 29396542
- Roth SM, et al. (2003). Myostatin gene expression is reduced in humans with heavy-resistance strength training: a brief communication. Experimental Biology and Medicine. PubMed 12773702
- Saremi A, et al. (2010). Effects of oral creatine and resistance training on serum myostatin and GASP-1. Molecular and Cellular Endocrinology. PubMed 20026378
- Schafer MJ, et al. (2016). Quantification of GDF11 and Myostatin in Human Aging and Cardiovascular Disease. Cell Metabolism. PubMed 27304512
- Yarasheski KE, et al. (2002). Serum myostatin-immunoreactive protein is increased in 60-92 year old women and men with muscle wasting. Journal of Nutrition, Health and Aging. PubMed 12474026